Compare Comcast Corporation (CMCSA) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs Crispr Therapeutics AG — how do they compare? Comcast Corporation trades at $25.63 (market cap $91.02B), while Crispr Therapeutics AG trades at $54 (market cap $5.23B). The key difference: Comcast Corporation is far larger — about 17.4× Crispr Therapeutics AG's market cap, and Comcast Corporation pays a 5.15% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CMCSA | CRSP | |
|---|---|---|
Market Cap | $91.02B | $5.23B |
Sector | Media | Health |
52-Week High | $32.50 | $76.78 |
52-Week Low | $21.92 | $44.34 |
Enterprise Value | $173.74B | $3.65B |
Dividend Yield | 5.15% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
